Skip to main content
Michael Mendelsohn, MD, Cardiology, Boston, MA

MichaelEMendelsohnMD

Cardiology Boston, MA

Chairman, Cardurion Pharmaceuticals, Inc. Professor of Medicine and Cardiology, Tufts University School of Medicine

Dr. Mendelsohn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mendelsohn's full profile

Already have an account?

  • Office

    New England Medical Ctre
    750 Washington Street
    Boston, MA 02111
    Phone+1 617-636-9370

Summary

  • Cardiovascular physician-scientist, research leader and business executive with broad experience in healthcare (cardiovascular and internal medicine, basic and clinical sciences, executive management). Founder and Executive Chairman of Cardurion Pharmaceuticals, a cardiovascular biotechnology company. Dr. Mendelsohn also serves currently as senior advisor and consultant to the head of R&D at Takeda Pharmaceuticals and as a Board Director of Foghorn Therapeutics and Broadview Ventures. From 2013-2017, Dr. Mendelsohn served as a venture partner at SV Health Investors.

    From 2010-2013, Dr. Mendelsohn served as SVP and Global Head of Cardiovascular Diseases, Merck & Co. Prior to Merck, Dr. Mendelsohn worked for 25 years as an academic cardiovascular physician-scientist in Boston. Dr. Mendelsohn received an undergraduate degree in Chemistry and English from Amherst College and his MD from Harvard Medical School (HMS) in 1982. From 1988-1993, he was an assistant professor of medicine on the faculty of HMS, a member of the BWH Cardiology Division and ran an independent, NIH-funded basic science laboratory focused on molecular cardiovascular biology. From 1993-2010, he moved to Tufts Medical Center, where served as the first executive director of the Molecular Cardiology Research Institute, In 2008, Dr. Mendelsohn was named Chief Scientific Officer at Tufts. In 2010, Dr. Mendelsohn was appointed senior vice president and global head of cardiovascular research at Merck Research Laboratories (MRL). He founded Cardurion Pharmaceuticals in 2017.

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Cardiovascular Disease, 1985 - 1987
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1982 - 1985
  • Harvard Medical School
    Harvard Medical SchoolClass of 1982

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1988 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Cardiovascular Disease

Publications & Presentations

PubMed

Press Mentions

  • Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors
    Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of DirectorsNovember 20th, 2019
  • Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation
    Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following SeparationJanuary 24th, 2019

Grant Support

  • Vascular Surgery - Estrogen And The Injury ResponseNational Heart, Lung, And Blood Institute2003–2009
  • Nitric Oxide Signaling Mechanisms In Vascular CellsNational Heart, Lung, And Blood Institute1996–2009
  • Molecular Mechanisms Of Vascular RelaxationNational Heart, Lung, And Blood Institute2004–2008
  • Training Program In Cardiovascular ResearchNational Heart, Lung, And Blood Institute2003–2007
  • Molecular Biology Of The VasculatureNational Heart, Lung, And Blood Institute2005
  • Cellular Fluorescence-Contractility Imaging System: Cardiovascular ResearchNational Center For Research Resources2005
  • Cellular Fluorescence-Contractility Imaging SystemNational Center For Research Resources2005
  • Core A-- Administration CoreNational Heart, Lung, And Blood Institute2004
  • Specialized Center Of Research In Ischemic Heart DiseaseNational Heart, Lung, And Blood Institute2000–2004
  • Estrogen Receptor Regulation Of NO SynthasesNational Heart, Lung, And Blood Institute2000–2004
  • Core A-- AdministrativeNational Heart, Lung, And Blood Institute2003
  • Vascular Estrogen Receptors--Molecular MechanismsNational Heart, Lung, And Blood Institute1998–2001
  • Vascular Surgery--Estrogen And The Injury ResponseNational Heart, Lung, And Blood Institute1997–1999
  • Endothelial-Derived Relaxing Factor &Platelet FunctionNational Heart, Lung, And Blood Institute1992–1993
  • Endothelial-Derived Relaxing Factor &Platelet FunctionNational Heart, Lung, And Blood Institute1989–1992